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Background
Aberrant DNA methylation and histone deacetylation
participate in cancer development and progression, hence
their reversal by inhibitors of DNA methylation and his-
tone deacetylases (HDACs) is undergoing clinical testing
in cancer therapy. As epigenetic alterations are common
to breast cancer, in this proof-of-concept study, the
demethylating hydralazine plus the HDACs inhibitor
magnesium valproate were added to neoadjuvant doxoru-
bicin and cyclophosphamide in locally advanced breast
cancer to assess their safety and biological efficacy.
Materials and methods
Patients were typed for acetylator phenotype and then
treated with hydralazine at 182 mg for rapid or 83 mg for
slow-acetylators, and magnesium valproate at 30 mg/Kg,
starting from day -7 until chemotherapy ended which
consisted in four cycles of doxorubicin 60 mg/m2 and
cyclophosphamide 600 mg/m2, every 21 days. Core nee-
dle biopsies were taken from the primary breast tumors at
diagnosis and at day 8 of treatment with hydralazine and
valproate.
Results
Sixteen patients were included and received treatment as
planed. All were evaluated for clinical response and toxic-
ity and 15 for pathological response. Treatment was well-
tolerated. The most common toxicity was drowsiness
grades 1–2. Five (31%) patients had clinical CR and eight
(50%) PR for an ORR of 81%. No one progressed. One
out of 15 operated patients (6.6%) had pathological CR
and 70% had residual disease <3 cm. There was a statisti-
cally significant decrease in global 5mC content and
HDAC activity. Hydralazine and magnesium valproate up
and down-regulated at least 3-fold, 1091 and 89 genes
respectively. Among up-regulated genes there were several
tumor suppressor genes including p53.
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Conclusion
Hydralazine and magnesium valproate produce DNA
demethylation, HDAC inhibition and gene reactivation in
the primary tumors. This treatment associated with doxo-
rubicin and cyclophosphamide is safe, well-tolerated and
seems to increase the efficacy of chemotherapy. A rand-
omized phase III study is ongoing to support the efficacy
of the so called epigenetic or transcriptional cancer ther-
apy.